Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Journal of the American College of Cardiology

Volumn 68, Issue 7, 2016, Pages 673-684

  Auffret, Vincent ^a,b   Regueiro, Ander ^a   Del Trigo, María ^a   Abdul Jawad Altisent, Omar ^a   Campelo Parada, Francisco ^a   Chiche, Olivier ^a   Puri, Rishi ^a   Rodés Cabau, Josep ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE RENNES 1   (France)

Author keywords

aortic stenosis; cerebrovascular events; predictors; stroke; transcatheter aortic valve implantation

Indexed keywords

ADULT; AORTA STENOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; ATRIAL FIBRILLATION; BALLOON DILATATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DUAL ANTIPLATELET THERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OBESITY; PERCUTANEOUS AORTIC VALVE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SELF EXPANDING STENT; SEX DIFFERENCE; SURGICAL APPROACH; SYSTEMATIC REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; AORTIC VALVE STENOSIS; COMPLICATION; GLOBAL HEALTH; INCIDENCE; PROGNOSIS; STROKE; TIME FACTOR;

AORTIC VALVE STENOSIS; GLOBAL HEALTH; HUMANS; INCIDENCE; PROGNOSIS; STROKE; TIME FACTORS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84994229453     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.05.065     Document Type: Article

References (101)

1. 1 Nishimura, R.A., Otto, C.M., Bonow, R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 63 (2014), e57–e185.
2. 2 Leon, M.B., Smith, C.R., Mack, M.J., et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 (2016), 1609–1620.
3. 3 Tamburino, C., Barbanti, M., D'Errigo, P., et al. 1-Year outcomes after transfemoral transcatheter or surgical aortic valve replacement: results from the Italian OBSERVANT study. J Am Coll Cardiol 66 (2015), 804–812.
4. 4 Thyregod, H.G., Steinbruchel, D.A., Ihlemann, N., et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol 65 (2015), 2184–2194.
5. 5 Athappan, G., Gajulapalli, R.D., Sengodan, P., et al. Influence of transcatheter aortic valve replacement strategy and valve design on stroke after transcatheter aortic valve replacement: a meta-analysis and systematic review of literature. J Am Coll Cardiol 63 (2014), 2101–2110.
6. 6 Eggebrecht, H., Schmermund, A., Voigtlander, T., Kahlert, P., Erbel, R., Mehta, R.H., Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 8 (2012), 129–138.
7. 7 Holmes, D.R., Brennan, J.M., Rumsfeld, J.S., et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA 313 (2015), 1019–1028.
8. 8 Adams, D.H., Popma, J.J., Reardon, M.J., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370 (2014), 1790–1798.
9. 9 Walther, T., Hamm, C.W., Schuler, G., et al. Perioperative results and complications in 15,964 transcatheter aortic valve replacements: prospective data from the GARY registry. J Am Coll Cardiol 65 (2015), 2173–2180.
10. 10 Reinohl, J., Kaier, K., Reinecke, H., et al. Effect of availability of transcatheter aortic-valve replacement on clinical practice. N Engl J Med 373 (2015), 2438–2447.
11. 11 Ludman, P.F., Moat, N., de Belder, M.A., et al. Transcatheter aortic valve implantation in the United Kingdom: Temporal trends, predictors of outcome, and 6-year follow-up: a report from the UK Transcatheter Aortic Valve Implantation (TAVI) Registry, 2007 to 2012. Circulation 131 (2015), 1181–1190.
12. 12 Freeman, M., Barbanti, M., Wood, D.A., et al. Cerebral events and protection during transcatheter aortic valve replacement. Catheter Cardiovasc Interv 84 (2014), 885–896.
13. 13 Hynes, B.G., Rodes-Cabau, J., Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art. Ann N Y Acad Sci 1254 (2012), 151–163.
14. 14 Fanning, J.P., Walters, D.L., Platts, D.G., Eeles, E., Bellapart, J., Fraser, J.F., Characterization of neurological injury in transcatheter aortic valve implantation: how clear is the picture?. Circulation 129 (2014), 504–515.
15. 15 Mastoris, I., Schoos, M.M., Dangas, G.D., Mehran, R., Stroke after transcatheter aortic valve replacement: incidence, risk factors, prognosis, and preventive strategies. Clin Cardiol 37 (2014), 756–764.
16. 16 Bosmans, J., Bleiziffer, S., Gerckens, U., et al. The incidence and predictors of early- and mid-term clinically relevant neurological events after transcatheter aortic valve replacement in real-world patients. J Am Coll Cardiol 66 (2015), 209–217.
17. 17 Tchetche, D., Farah, B., Misuraca, L., et al. Cerebrovascular events post-transcatheter aortic valve replacement in a large cohort of patients: a FRANCE-2 registry substudy. J Am Coll Cardiol Intv 7 (2014), 1138–1145.
18. 18 Miller, D.C., Blackstone, E.H., Mack, M.J., et al. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 143 (2012), 832–843.e13.
19. 19 Stortecky, S., Windecker, S., Pilgrim, T., et al. Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention 8 (2012), 62–70.
20. 20 Nombela-Franco, L., Webb, J.G., de Jaegere, P.P., et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 126 (2012), 3041–3053.
21. 21 Nuis, R.J., Van Mieghem, N.M., Schultz, C.J., et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 109 (2012), 1637–1643.
22. 22 Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3 (2009), e123–e130.
23. 23 DerSimonian, R., Laird, N., Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
24. 24 Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
25. 25 Harbord, R.M., Egger, M., Sterne, J.A., A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med 25 (2006), 3443–3457.
26. 26 Leker, R.R., Eichel, R., Verber, A., Cohen, J.E., Lotan, C., Danenberg, H.D., Stroke complicating transcatheter aortic valve implantation: Incidence, risk factors and outcome. Int J Stroke 8 (2013), 235–239.
27. 27 Stangl, V., Baldenhofer, G., Knebel, F., et al. Impact of gender on three-month outcome and left ventricular remodeling after transfemoral transcatheter aortic valve implantation. Am J Cardiol 110 (2012), 884–890.
28. 28 O'Connor, S.A., Morice, M.C., Gilard, M., et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. J Am Coll Cardiol 66 (2015), 221–228.
29. 29 Sherif, M.A., Zahn, R., Gerckens, U., et al. Effect of gender differences on 1-year mortality after transcatheter aortic valve implantation for severe aortic stenosis: results from a multicenter real-world registry. Clin Res Cardiol 103 (2014), 613–620.
30. 30 Abramowitz, Y., Chakravarty, T., Jilaihawi, H., et al. Comparison of outcomes of transcatheter aortic valve implantation in patients ≥90 years versus <90 years. Am J Cardiol 116 (2015), 1110–1115.
31. 31 Yamamoto, M., Meguro, K., Mouillet, G., et al. Comparison of effectiveness and safety of transcatheter aortic valve implantation in patients aged ≥90 years versus <90 years. Am J Cardiol 110 (2012), 1156–1163.
32. 32 Konigstein, M., Havakuk, O., Arbel, Y., et al. The obesity paradox in patients undergoing transcatheter aortic valve implantation. Clin Cardiol 38 (2015), 76–81.
33. 33 Yamamoto, M., Mouillet, G., Oguri, A., et al. Effect of body mass index on 30- and 365-day complication and survival rates of transcatheter aortic valve implantation (from the FRench Aortic National CoreValve and Edwards 2 [FRANCE 2] registry). Am J Cardiol 112 (2013), 1932–1937.
34. 34 Conrotto, F., D'Ascenzo, F., Giordana, F., et al. Impact of diabetes mellitus on early and midterm outcomes after transcatheter aortic valve implantation (from a multicenter registry). Am J Cardiol 113 (2014), 529–534.
35. 35 Minha, S., Magalhaes, M.A., Barbash, I.M., et al. The impact of diabetes mellitus on outcome of patients undergoing transcatheter aortic valve replacement. IJC Metabolic and Endocrine 9 (2015), 54–60.
36. 36 Barbash, I.M., Minha, S., Ben-Dor, I., et al. Predictors and clinical implications of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 85 (2015), 468–477.
37. 37 Chopard, R., Teiger, E., Meneveau, N., et al. Baseline characteristics and prognostic implications of pre-existing and new-onset atrial fibrillation after transcatheter aortic valve implantation: results from the FRANCE-2 registry. J Am Coll Cardiol Intv 8 (2015), 1346–1355.
38. 38 Maan, A., Heist, E.K., Passeri, J., et al. Impact of atrial fibrillation on outcomes in patients who underwent transcatheter aortic valve replacement. Am J Cardiol 115 (2015), 220–226.
39. 39 Yankelson, L., Steinvil, A., Gershovitz, L., et al. Atrial fibrillation, stroke, and mortality rates after transcatheter aortic valve implantation. Am J Cardiol 114 (2014), 1861–1866.
40. 40 Abdel-Wahab, M., Zahn, R., Horack, M., et al. Transcatheter aortic valve implantation in patients with and without concomitant coronary artery disease: comparison of characteristics and early outcome in the German multicenter TAVI registry. Clin Res Cardiol 101 (2012), 973–981.
41. 41 Abramowitz, Y., Banai, S., Katz, G., et al. Comparison of early and late outcomes of TAVI alone compared to TAVI plus PCI in aortic stenosis patients with and without coronary artery disease. Catheter Cardiovasc Interv 83 (2014), 649–654.
42. 42 Gautier, M., Pepin, M., Himbert, D., et al. Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes. EuroIntervention 7 (2011), 549–555.
43. 43 Mancio, J., Fontes-Carvalho, R., Oliveira, M., et al. Coronary artery disease and symptomatic severe aortic valve stenosis: clinical outcomes after transcatheter aortic valve implantation. Front Cardiovasc Med, 2, 2015, 18.
44. 44 Snow, T.M., Ludman, P., Banya, W., et al. Management of concomitant coronary artery disease in patients undergoing transcatheter aortic valve implantation: the United Kingdom TAVI Registry. Int J Cardiol 199 (2015), 253–260.
45. 45 Stefanini, G.G., Stortecky, S., Cao, D., et al. Coronary artery disease severity and aortic stenosis: clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur Heart J 35 (2014), 2530–2540.
46. 46 Allende, R., Webb, J.G., Munoz-Garcia, A.J., et al. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. Eur Heart J 35 (2014), 2685–2696.
47. 47 Ferro, C.J., Chue, C.D., De Belder, M.A., et al. Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. Heart 101 (2015), 546–552.
48. 48 Nguyen, T.C., Babaliaros, V.C., Razavi, S.A., et al. Impact of varying degrees of renal dysfunction on transcatheter and surgical aortic valve replacement. J Thorac Cardiovasc Surg 146 (2013), 1399–1406.
49. 49 Oguri, A., Yamamoto, M., Mouillet, G., et al. Impact of chronic kidney disease on the outcomes of transcatheter aortic valve implantation: results from the FRANCE 2 registry. EuroIntervention 10 (2015), e1–e9.
50. 50 Sinning, J.M., Horack, M., Grube, E., et al. The impact of peripheral arterial disease on early outcome after transcatheter aortic valve implantation: results from the German Transcatheter Aortic Valve Interventions Registry. Am Heart J 164 (2012), 102–110.e1.
51. 51 Bosmans, J.M., Kefer, J., De Bruyne, B., et al. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian National Registry. Interact Cardiovasc Thorac Surg 12 (2011), 762–767.
52. 52 Eltchaninoff, H., Prat, A., Gilard, M., et al. Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 32 (2011), 191–197.
53. 53 Ewe, S.H., Delgado, V., Ng, A.C., et al. Outcomes after transcatheter aortic valve implantation: transfemoral versus transapical approach. Ann Thorac Surg 92 (2011), 1244–1251.
54. 54 Fröhlich, G.M., Baxter, P.D., Malkin, C.J., et al. Comparative survival after transapical, direct aortic, and subclavian transcatheter aortic valve implantation (Data from the UK TAVI Registry). Am J Cardiol 116 (2015), 1555–1559.
55. 55 Imnadze, G., Franz, N., Hofmann, S., et al. Benefits of best for groin strategy leading to a transapical TAVI dominance. Thorac Cardiovasc Surg 63 (2015), 487–492.
56. 56 Lotfi, S., Dohmen, G., Gotzenich, A., et al. Midterm outcomes after transcatheter aortic valve implantation. Innovations (Phila) 9 (2014), 343–347.
57. 57 Mack, M.J., Brennan, J.M., Brindis, R., et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA 310 (2013), 2069–2077.
58. 58 Muensterer, A., Mazzitelli, D., Ruge, H., et al. Safety and efficacy of the subclavian access route for TAVI in cases of missing transfemoral access. Clin Res Cardiol 102 (2013), 627–636.
59. 59 Petronio, A.S., De Carlo, M., Bedogni, F., et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv 3 (2010), 359–366.
60. 60 Schymik, G., Wurth, A., Bramlage, P., et al. Long-term results of transapical versus transfemoral TAVI in a real world population of 1000 patients with severe symptomatic aortic stenosis. Circ Cardiovasc Interv, 8, 2015.
61. 61 Seiffert, M., Schnabel, R., Conradi, L., et al. Predictors and outcomes after transcatheter aortic valve implantation using different approaches according to the valve academic research consortium definitions. Catheter Cardiovasc Interv 82 (2013), 640–652.
62. 62 Walters, D.L., Sinhal, A., Baron, D., et al. Initial experience with the balloon expandable Edwards-SAPIEN Transcatheter Heart Valve in Australia and New Zealand: The SOURCE ANZ registry: outcomes at 30 days and one year. Int J Cardiol 170 (2014), 406–412.
63. 63 Webb, J., Gerosa, G., Lefevre, T., et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol 64 (2014), 2235–2243.
64. 64 Abdel-Wahab, M., Mehilli, J., Frerker, C., et al. Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transcatheter aortic valve replacement: the CHOICE randomized clinical trial. JAMA 311 (2014), 1503–1514.
65. 65 TAVI annual report 2011. Scand Cardiovas J 47 (2013), 95–102.
66. 66 Chieffo, A., Buchanan, G.L., Van Mieghem, N.M., et al. Transcatheter aortic valve implantation with the Edwards SAPIEN versus the Medtronic CoreValve Revalving system devices: a multicenter collaborative study: the PRAGMATIC Plus Initiative (Pooled-RotterdAm-Milano-Toulouse In Collaboration). J Am Coll Cardiol 61 (2013), 830–836.
67. 67 Collas, V.M., Dubois, C., Legrand, V., et al. Midterm clinical outcome following Edwards SAPIEN or Medtronic Corevalve transcatheter aortic valve implantation (TAVI): results of the Belgian TAVI registry. Catheter Cardiovasc Interv 86 (2015), 528–535.
68. 68 Kasel, A.M., Cassese, S., Ischinger, T., et al. A prospective, non-randomized comparison of SAPIEN XT and CoreValve implantation in two sequential cohorts of patients with severe aortic stenosis. Am J Cardiovasc Dis 4 (2014), 87–99.
69. 69 Sabaté, M., Cánovas, S., García, E., et al. In-hospital and mid-term predictors of mortality after transcatheter aortic valve implantation: data from the TAVI National Registry 2010-2011. Rev Esp Cardiol 66 (2013), 949–958.
70. 70 Watanabe, Y., Hayashida, K., Yamamoto, M., et al. Transfemoral aortic valve implantation in patients with an annulus dimension suitable for either the Edwards valve or the CoreValve. Am J Cardiol 112 (2013), 707–713.
71. 71 Wenaweser, P., Pilgrim, T., Roth, N., et al. Clinical outcome and predictors for adverse events after transcatheter aortic valve implantation with the use of different devices and access routes. Am Heart J 161 (2011), 1114–1124.
72. 72 Wenaweser, P., Stortecky, S., Heg, D., et al. Short-term clinical outcomes among patients undergoing transcatheter aortic valve implantation in Switzerland: the Swiss TAVI registry. EuroIntervention 10 (2014), 982–989.
73. 73 Lange, R., Bleiziffer, S., Mazzitelli, D., et al. Improvements in transcatheter aortic valve implantation outcomes in lower surgical risk patients: a glimpse into the future. J Am Coll Cardiol 59 (2012), 280–287.
74. 74 Makkar, R.R., Jilaihawi, H., Chakravarty, T., et al. Determinants and outcomes of acute transcatheter valve-in-valve therapy or embolization: a study of multiple valve implants in the U.S. PARTNER trial (Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve). J Am Coll Cardiol 62 (2013), 418–430.
75. 75 Geisbusch, S., Bleiziffer, S., Mazzitelli, D., Ruge, H., Bauernschmitt, R., Lange, R., Incidence and management of CoreValve dislocation during transcatheter aortic valve implantation. Circ Cardiovasc Interv 3 (2010), 531–536.
76. 76 Barbanti, M., Petronio, A.S., Capodanno, D., et al. Impact of balloon post-dilation on clinical outcomes after transcatheter aortic valve replacement with the self-expanding CoreValve prosthesis. J Am Coll Cardiol Intv 7 (2014), 1014–1021.
77. 77 Hahn, R.T., Pibarot, P., Webb, J., et al. Outcomes with post-dilation following transcatheter aortic valve replacement: the PARTNER I trial (placement of aortic transcatheter valve). J Am Coll Cardiol Intv 7 (2014), 781–789.
78. 78 Lasa, G., Gaviria, K., Sanmartin, J.C., Telleria, M., Larman, M., Postdilatation for treatment of perivalvular aortic regurgitation after transcatheter aortic valve implantation. Catheter Cardiovasc Interv 83 (2014), E112–E118.
79. 79 Stundl, A., Rademacher, M.C., Descoups, C., et al. Balloon post-dilation and valve-in-valve implantation for the reduction of paravalvular leakage with use of the self-expanding CoreValve prosthesis. EuroIntervention 11 (2016), 1140–1147.
80. 80 Watanabe, Y., Hayashida, K., Lefèvre, T., et al. Is post-dilation useful after implantation of the Edwards valve?. Catheter Cardiovasc Interv 85 (2015), 667–676.
81. 81 Durand, E., Blanchard, D., Chassaing, S., et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 113 (2014), 355–360.
82. 82 Huczek, Z., Kochman, J., Grygier, M., et al. Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve implantation (TAVI). Thromb Res 136 (2015), 112–117.
83. 83 Poliacikova, P., Cockburn, J., De Belder, A., Trivedi, U., Hildick-Smith, D., Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation: comparison of regimes. J Invasive Cardiol 25 (2013), 544–548.
84. 84 Stabile, E., Pucciarelli, A., Cota, L., et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 174 (2014), 624–627.
85. 85 Ussia, G.P., Scarabelli, M., Mul, M., et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 108 (2011), 1772–1776.
86. 86 Leon, M.B., Piazza, N., Nikolsky, E., et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol 57 (2011), 253–269.
87. 87 Kappetein, A.P., Head, S.J., Généreux, P., et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol 60 (2012), 1438–1454.
88. 88 Smith, C.R., Leon, M.B., Mack, M.J., et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
89. 89 Cramariuc, D., Rogge, B.P., Lonnebakken, M.T., et al. Sex differences in cardiovascular outcome during progression of aortic valve stenosis. Heart 101 (2015), 209–214.
90. 90 Devereux, R.B., de Simone, G., Arnett, D.K., et al. Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons >/=15 years of age. Am J Cardiol 110 (2012), 1189–1194.
91. 91 Buellesfeld, L., Stortecky, S., Kalesan, B., et al. Aortic root dimensions among patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. J Am Coll Cardiol Intv 6 (2013), 72–83.
92. 92 Van Mieghem, N.M., El Faquir, N., Rahhab, Z., et al. Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. J Am Coll Cardiol Intv 8 (2015), 718–724.
93. 93 Rodés-Cabau, J., Pibarot, P., Suri, R.M., et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER trial. Circ Cardiovasc Interv 7 (2014), 701–711.
94. 94 Toyoda, K., Ninomiya, T., Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol 13 (2014), 823–833.
95. 95 Vellanki, K., Bansal, V.K., Neurologic complications of chronic kidney disease. Curr Neurol Neurosc Rep, 15, 2015, 50.
96. 96 Minha, S., Waksman, R., Satler, L.P., et al. Learning curves for transfemoral transcatheter aortic valve replacement in the PARTNER-I trial: success and safety. Catheter Cardiovasc Interv 87 (2016), 165–175.
97. 97 Athappan, G., Patvardhan, E., Tuzcu, E.M., et al. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol 61 (2013), 1585–1595.
98. 98 Nombela-Franco, L., Rodés-Cabau, J., DeLarochelliere, R., et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol Intv 5 (2012), 499–512.
99. 99 Binder, R.K., Stortecky, S., Heg, D., et al. Procedural results and clinical outcomes of transcatheter aortic valve implantation in Switzerland: an observational cohort study of Sapien 3 Versus Sapien XT transcatheter heart valves. Circ Cardiovasc Interv, 8, 2015 pii:e002653.
100. 100 Meredith Am, I.T., Walters, D.L., Dumonteil, N., et al. Transcatheter aortic valve replacement for severe symptomatic aortic stenosis using a repositionable valve system: 30-day primary endpoint results from the REPRISE II study. J Am Coll Cardiol 64 (2014), 1339–1348.
101. 101 Amat-Santos, I.J., Rodes-Cabau, J., Urena, M., et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 59 (2012), 178–188.